Citadel Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Citadel Advisors’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-35,597	Closed	-$22K	–	10417
2018 Q4	$22K	Sell	35,597 -33,120	-48%	-$34.4K	﹤0.01%	8727
2018 Q3	$89K	Buy	68,717 +34,174	+99%	+$53.1K	﹤0.01%	8623
2018 Q2	$47K	Buy	+34,543	New	+$52.9K	﹤0.01%	8451
2018 Q1	–	Sell	-32,307	Closed	-$73K	–	9270
2017 Q4	$73K	Buy	+32,307	New	+$81.8K	﹤0.01%	7524
2017 Q3	–	Sell	-17,251	Closed	-$58K	–	8572
2017 Q2	$61K	Buy	+17,251	New	+$56.8K	﹤0.01%	7052
2015 Q3	–	Sell	-21,100	Closed	-$97K	–	9718
2015 Q2	$97K	Buy	+21,100	New	+$202K	﹤0.01%	7111

Citadel Advisors's AST Position: Q1 2019 in Review

Citadel Advisors sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 35,597 shares — an estimated $22K sold.

Citadel Advisors first reported a position in AST in Q2 2015 and held it in 6 quarters. The position peaked at $97K in Q2 2015. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

Citadel Advisors reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
Citadel Advisors sold 35,597 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $22K.
Citadel Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 6 quarters.
Citadel Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $97K in Q2 2015.
0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.